Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12596028 | 0.98 | SLC6A4 (0.53) | SLC6A3SLC6A4SLC6A2HDAC4CCR2 | |
| SCHEMBL436499 | 0.95 | SLC6A4 (0.46) | SLC6A3SLC6A4SLC6A2HDAC4CCR2 | |
| SCHEMBL435094 | 0.90 | SLC6A4 (0.44) | SLC6A3SLC6A4SLC6A2CCR2DRD2 | |
| Hydrochloric Acid SCHEMBL29020111 | 0.86 | OPRM1 (0.42) | SLC6A3SLC6A4SLC6A2CCR2DRD2 | |
| SCHEMBL10602015 | 0.85 | ESR1 (0.42) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL17807530 | 0.80 | ALDH1A1 (0.41) | SLC6A3SLC6A4SLC6A2DRD2DRD4 | |
| SCHEMBL655680 | 0.80 | DRD2 (0.60) | SLC6A3SLC6A4SLC6A2CCR2DRD2 | |
| SCHEMBL22815284 | 0.79 | CYP1A2 (0.44) | SLC6A3SLC6A4SLC6A2EPHX2DRD2 | |
| Hydrochloric Acid SCHEMBL23858321 | 0.79 | DRD2 (0.58) | SLC6A3SLC6A4SLC6A2CCR2DRD2 | |
| SCHEMBL13452620 | 0.79 | OPRM1 (0.57) | DRD2HSD11B1DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20160346384-A1 | MODIFIED GLYCOLIPIDS AND METHODS OF MAKING AND USING THE SAME | VACCINEX, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-9371352-B2 | Modified glycolipids and methods of making and using the same | VACCINEX, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-9326973-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-9139809-B2 | Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-20140227296-A1 | MODIFIED GLYCOLIPIDS AND METHODS OF MAKING AND USING THE SAME | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2014-08-14 | — | — | US | disclosed |
| US-7355053-B2 | 1-phenylpyrrolidine-2-one-3-carboxamides | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-08 | — | — | US | disclosed |
| US-7335773-B2 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335773-B2 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7304077-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-12-04 | — | — | US | disclosed |
| US-7304077-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-12-04 | — | — | US | disclosed |
| US-20070238673-A1 | Ceramide derivatives as modulators of immunity and autoimmunity | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2007-10-11 | — | — | US | disclosed |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| WO-2005009392-A2 | DIHYDROPYRIMIDONE INHIBITORS OF CALCIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227296-A1 | MODIFIED GLYCOLIPIDS AND METHODS OF MAKING AND USING THE SAME | CERT1, UGCG, SGMS1 | SLC6A3 4830/4885SLC6A4 4836/4885SLC6A2 4750/4885 |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | IFNG, IRF3, IFNAR1 | SLC6A3 2575/4885SLC6A4 2420/4885SLC6A2 3861/4885 |
| US-20070238673-A1 | Ceramide derivatives as modulators of immunity and autoimmunity | CERS2, UGCG, SGMS1 | SLC6A3 4298/4885SLC6A4 4473/4885SLC6A2 3842/4885 |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | SLC6A3 3379/4885SLC6A4 3790/4885SLC6A2 3944/4885 |
| US-20160346384-A1 | MODIFIED GLYCOLIPIDS AND METHODS OF MAKING AND USING THE SAME | CERT1, UGCG, SGMS1 | SLC6A3 4830/4885SLC6A4 4836/4885SLC6A2 4750/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | SLC6A3 3379/4885SLC6A4 3790/4885SLC6A2 3944/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | SLC6A3 3730/4885SLC6A4 4154/4885SLC6A2 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.